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Abstract Endomorphins (EMs), two endogenous l-opi-
oid receptor selective ligands, are attractive lead com-
pounds for opioid-based pain management studies.
However, these peptides are quickly degraded by pepti-
dases, in particular by dipeptidylpeptidase IV (DPP IV) and
aminopeptidase M (APM). Targeting enzymatic degrada-
tion is one approach to prolong endomorphin activity. In
this study we characterized the action of two new inhibitors
of similar to endomorphins structure, Tyr-Pro-Ala-NH2
(EMDB-2) and Tyr-Pro-Ala-OH (EMDB-3), which were
designed earlier in our laboratory. The presented data give
evidence that EMDB-2 and EMDB-3 are potent inhibitors
of enzymes responsible for endomorphin cleavage. These
compounds are stable and easily synthesized. EMDB-2 and
EMDB-3 are competitive inhibitors of both, DPP IV and
APM, with Ki values in micromolar range. They are less
potent than diprotin A in protecting EMs against DPP IV
but more potent than actinonin in protecting these peptides
against APM.
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Introduction
At present, the treatment of severe pain relies mostly upon
administration of centrally acting opiates such as morphine
and its surrogates, which target l-opioid receptors in the
brain.Inspiteofthepowerfulinvivoefﬁcacyofthesedrugs,
their long-term use is limited by a number of well-known
side-effects, including tolerance, physical dependence,
respiratory depression, and diverse gastrointestinal effects.
Discovery of endogenous l-opioid receptor ligands, endo-
morphin-1 (EM-1, Tyr-Pro-Trp-Phe-NH2), and endomor-
phin-2 (EM-2, Tyr-Pro-Phe-Phe-NH2) more than a decade
ago (Zadina et al., 1997) initiated extensive studies on the
possible use of these peptides as analgesics instead of
morphine. EMs exhibit outstanding potencies towards both,
acute and chronic neuropathic pain, as was demonstrated in
rodents in various types of pain tests (Narita et al., 1999;
Horvath et al., 1999; Horvath, 2000; Przewłocki and
Przewłocka, 2001; Grass et al., 2002). Furthermore, poten-
tially advantageous pharmacological properties of EMs are
the possible dissociation of analgesic and rewarding effects
in the rat (Wilson et al., 2000) and the moderate respiratory
depression when compared with morphine (Czapla et al.,
2000; Fichna et al., 2007). However, the main limitations of
the use of EMs as analgesics are short duration of action and
lack of activity after oral administration, both due to the
poor metabolic stability of these peptides (Shane et al.,
1999; Tomboly et al., 2002). Applying chemical modiﬁca-
tions to the structure of EMs is one strategy to obtain
compounds with desired pharmacological proﬁle.
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endogenous EMs by the use of peptidase inhibitors. The
enzyme which is primarily involved in the ﬁrst cleavage
step of EMs is a serine peptidase, dipeptidyl peptidase IV
(DPP IV), which liberates Tyr–Pro dipeptides from amino
terminus of EMs (Mentlein, 1999; Tomboly et al., 2002).
Proline-speciﬁc aminopeptidase M (APM) further splits the
obtained fragments of EMs (Sakurada et al., 2003) (Fig. 1).
Degradation of EMs can be signiﬁcantly blocked by
protease inhibitors. The most often used inhibitors of DPP
IV are tripeptides Ile-Pro-Ile (diprotin A) and Val-Pro-Leu
(diprotin B) (Mentlein, 1999). The action of APM is
inhibited by actinonin (Sugimoto-Watanabe et al., 1999;
Tomboly et al., 2002). Sakurada et al. (2003) showed that
simultaneous administration of EM-2 and diprotin A to the
mouse brain resulted in a ﬁvefold longer duration of
analgesic action compared with EM-2 alone. Actinonin
signiﬁcantly blocked EM-1 degradation in rat spinal cord
homogenate (Sugimoto-Watanabe et al., 1999).
In the search for effective blockers of EM degrading
enzymes, we have synthesized several tri- and tetrapeptides
with similar to EMs structure but with low l-opioid
receptor afﬁnities and tested them as possible inhibitors.
Two of these peptides, Tyr-Pro-Ala-NH2 (EMDB-2) and
Tyr-Pro-Ala-OH (EMDB-3), turned out to be effective
blockers of EM degradation by rat brain homogenate
(Fichna et al., 2006). The action of these two tripeptides
was further investigated in rat ileum in vitro (Fichna et al.,
2010). They both signiﬁcantly prolonged the inhibitory
effect of EM-2 on smooth muscle contractility in rat ileum.
The aim of this study was to investigate how these
tripeptides inﬂuence enzymatic cleavage of EMs by puri-
ﬁed enzymes, DPP IV and APM, and what type of inhi-
bition they represent.
Materials and methods
Peptide synthesis
Peptides were synthesized by a solid phase method on
MBHA Rink amide resin for C-terminally amidated ana-
logs and on Wang resin for peptide acids, using Fmoc
strategy and were puriﬁed by HPLC, as described earlier
(Fichna et al., 2006).
Determination of EM degradation rates
The degradation studies were performed using pure, com-
mercially available enzymes. DPP IV was used at a con-
centration of 0.002 mg protein/ml and APM at a
concentration of 0.06 mg protein/ml. Solutions of EMs and
inhibitors were made by dissolving them in Tris–HCl
buffer (50 mM, pH 7.4) to obtain 1 mM concentrations.
Enzymes, EMs and inhibitors were incubated over 0, 7.5,
15, 22.5, and 30 min at 37C in a ﬁnal volume of 200 ll.
The reaction was stopped at the required time by placing
the tube on ice and acidifying with 20 ll of 1 M aqueous
HCl solution. The aliquots were centrifuged at
20,0009g for 10 min at 4C. The obtained supernatants
were ﬁltered over Millipore Millex-GV syringe ﬁlters
(Millipore) and analyzed by RP-HPLC on a Vydac C18
column (5 lm, 4.6 mm 9 250 mm), using the solvent
system of 0.1% TFA in water (A) and 80% acetonitrile in
water containing 0.1% TFA (B) and a linear gradient of
0–100% B over 25 min. Three independent experiments
for each assay were carried out in duplicate. The rate
constants of degradation (k) were obtained as described
earlier (Tomboly et al., 2002), by the least square linear
regression analysis of logarithmic endomorphin peak areas
(ln(A/A0), where A the amount of peptide remaining, A0
initial amount of peptide versus time. Degradation half-
lives (t1/2) were calculated from the rate constants as ln 2/k.
Measurement of inhibition of proteolytic activity
of DPP4 and APM
The inhibitory potency of each inhibitor was determined at
ﬁve concentrations of substrate (1.25, 0.625, 0.25, 0.125,
and 0.0625 mM). Reaction was initiated by addition of
enzyme (DPP IV or APM) to solution containing substrate
(EM-1 or EM-2) and inhibitor (EMDB-2 or EMDB-3). In
each case, the reaction was allowed to proceed at 37C for
0, 7.5, 15, 22.5, and 30 min as described in a previous
section.
Statistical analysis
Statistical and curve-ﬁtting analyses were performed using
Prism 4.0 (GraphPad Software Inc.). The data are expres-
sed as means ± SEM. Differences between groups were
assessed by one-way analysis of variance (ANOVA), fol-
lowed by Student–Newman–Keul’s test.
Values of percentage inhibition of EM degradation were
calculated using following formula, which was described
earlier (Tomboly et al., 2002): Fig. 1 Scheme of EM metabolism in the brain
1446 Med Chem Res (2012) 21:1445–1450
123Inhibition % ðÞ ¼k0   ki ðÞ =k0   100;
where k0 the rate constant of degradation without inhibitor,
ki the rate constant of degradation with inhibitor.
Results
Effect of inhibitors on degradation of EMs by DPP IV
We evaluated EMDB-2 and EMDB-3 for their inhibitory
effect on degradation of EMs by DPP IV. Diprotin A was
included in the study for comparison. Degradation of EMs
was analyzed by reversed phase HPLC. Effects of 30 min
incubation of EM-2 with DPP IV in the absence and
presence of inhibitors are shown in Fig. 2. The chromato-
graphic peak area of EM-2 was found to decrease greatly in
the sample without inhibitors. Diprotin A almost com-
pletely suppressed enzymatic cleavage of EM-2, while
EMDB-2 and EMDB-3 only partially protected EM-2
against hydrolysis. Degradation rates and half-lives of EMs
alone and in the presence of inhibitors are collected in
Table 1. Different rates of degradation of EM-1 and EM-2
by DPP IV were observed. EM-1 was about 1.5 times more
resistant to DPP IV than EM-2, which is in agreement with
the data obtained by others (Tomboly et al., 2002; Grass
et al., 2002; Fujita and Kumamoto, 2006; Keresztes et al.,
2010). EMDB-2 and EMDB-3 increased EM-1 and EM-2
half-lives two- to threefold. The effects of inhibitors on
degradation of EMs after 30 min incubation with DPP IV
Fig. 2 Effect of inhibitors on
the degradation of EM-2 by
DPP IV. The reaction mixture
was incubated at 37C for
30 min in the absence (a) and
presence of diprotin A (b),
EMDB-2 (c), and EMDB-3 (d).
Asterisk indicates the peak
derived from the inhibitor added
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better DPP IV inhibitor than EMDB-2. The Lineweaver–
Burk plots revealed that both tested compounds acted as
competitive inhibitors of DPP IV (Fig. 3).
Effect of inhibitors on degradation of EMs by APM
EMDB-2 and EMDB-3 were then tested for their inhibitory
effect on the degradation of EMs by APM. The known
APM inhibitor, actinonin, was included for comparison.
Degradation rates and half-lives of EMs alone and in the
presence of inhibitors are collected in Table 3. EM-2 was
slightly more resistant to APM degradation than EM-1,
which is in agreement with earlier data by Peter et al.
(1999). Both tested compounds turned out to be better
inhibitors of EM degradation by APM than actinonin. The
effect of inhibitors on degradation of EMs is summarized
in Table 4. The Lineweaver–Burk plots revealed that both
new compounds acted as competitive inhibitors of APM
(Fig. 4).
Discussion
The degradation of EMs is responsible for the fact that their
analgesic activity decreases in time. Few inhibitors of DPP
IV are described in the literature and all of them have
limitations in terms of potency, stability or toxicity. Among
them diprotin A and diprotin B are probably the best known
and commercially available. They are competitive sub-
strates that are slowly hydrolyzed and act as inhibitors for
DPP IV at micromolar concentrations (Schon et al., 1991).
Table 1 Degradation rates (k) and half-lives (t1/2) of EMs incubated with DPP IV alone and in the presence of inhibitors
Inhibitor DPP IV
EM-1 EM-2
100 9 k (1/min) t1/2 (min) 100 9 k (1/min) t1/2 (min)
Without inhibitor 4.12 ± 0.2 16.7 ± 0.52 6.30 ± 0.31 10.9 ± 0.64
Diprotin A 0.13 ± 0.01 530 ± 14.5*** 0.18 ± 0.01 383 ± 20.2***
Tyr-Pro-Ala-NH2 (EMDB-2) 3.02 ± 0.09 22.9 ± 1.14* 3.48 ± 0.13 19.8 ± 0.75*
Tyr-Pro-Ala-OH (EMDB-3) 2.51 ± 0.12 27.5 ± 1.21* 2.52 ± 0.13 27.4 ± 1.41*
* P\0.05, *** P\0.001 as compared to respective EM incubated in the absence of inhibitor by using one-way ANOVA followed by Student–
Newman–Keul’s test
Table 2 The effect of inhibitors on the degradation of EMs by DPP IV
Inhibitor DPP IV
EM-1 EM-2
Inhibition (%) Ki (lM) Inhibition (%) Ki (lM)
Diprotin A 96.8 ± 3.27 2.2
a 97.1 ± 4.00 2.2
a
Tyr-Pro-Ala-NH2 (EMDB-2) 26.7 ± 1.20 420 44.8 ± 2.51 170
Tyr-Pro-Ala-OH (EMDB-3) 39.1 ± 1.41 270 60.0 ± 2.27 100
a Value taken from Ref. Umezawa et al. (1984)
Fig. 3 Lineweaver–Burk diagrams for the inhibition of DPP IV by
EMDB-2 and EMDB-3 in case of EM-1 (a) and EM-2 (b)
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dipeptides containing boroPro, the boronic acid analog of
Pro at the C-terminus (Flentke et al., 1991). Although
these compounds inhibit DPP IV action at nanomolar
concentrations,theyarequiteunstableandthatgreatlylimits
their use. Dipeptide phosphonates described by Boduszek
et al. (1994) are irreversible inhibitors of DPP IV, which are
speciﬁc but not very potent. The series of aminoacylpyrro-
lidine-2-nitriles obtained by Li et al. (1995), that have Ki
valuesinthemicromolarrange,areanothergroupofspeciﬁc
DPP IV inhibitors with good potency and stability.
The studies presented here give evidence that EMDB-2
and EMDB-3 are potent inhibitors of enzymes responsible
for EM cleavage. These compounds are stable and easily
synthesized. EMDB-2 and EMDB-3 are competitive
inhibitors of both, DPP IV and APM, with Ki values in
submillimolar range. They are less potent than diprotin A
in protecting EMs against DPP IV, but more potent than
actinonin in protecting these peptides against APM.
So far we have shown that two new blockers of EM
degrading enzymes, EMDB-2 and EMDB-3 signiﬁcantly
prolonged the inhibitory effects of EM-2 in gastrointestinal
smooth muscle preparations (Fichna et al., 2010). In vivo
studies are under way to establish if these inhibitors can
also prolong analgesic effect produced by exogenously
administered EMs. Interestingly, preliminary results
showed that EMDB-2 and EMDB-3 do not cross the
blood–brain barrier, suggesting that their action is limited
to the periphery after systemic administration.
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Table 3 Degradation rates (k) and half-lives (t1/2) of EMs incubated with APM alone and in the presence of inhibitors
Inhibitor APM
EM-1 EM-2
100 9 k (1/min) t1/2 (min) 100 9 k (1/min) t1/2 (min)
Without inhibitor 3.51 ± 0.09 19.7 ± 0.50 2.96 ± 0.12 23.3 ± 0.98
Actinonin 1.88 ± 0.09 36.8 ± 2.10*** 1.50 ± 0.05 46.3 ± 1.16**
Tyr-Pro-Ala-NH2 (EMDB-2) 1.63 ± 0.06 42.3 ± 1.89*** 1.28 ± 0.04 53.9 ± 1.53***
Tyr-Pro-Ala-OH (EMDB-3) 1.58 ± 0.05 43.7 ± 1.73*** 1.44 ± 0.07 47.9 ± 2.14***
** P\0.01, *** P\0.001 as compared to respective EM incubated in the absence of inhibitor by using one-way ANOVA followed by
Student–Newman–Keul’s test
Fig. 4 Lineweaver–Burk diagrams for the inhibition of APM by
EMDB-2 and EMDB-3 in case of EM-1 (a) and EM-2 (b)
Table 4 The effect of inhibitors on the degradation of EMs by APM
Inhibitor APM
EM-1 EM-2
Inhibition (%) Ki (lM) Inhibition (%) Ki (lM)
Actinonin 46.2 ± 0.55 390 49.3 ± 0.90 300
Tyr-Pro-Ala-NH2 (EMDB-2) 53.6 ± 1.21 130 56.8 ± 1.62 80
Tyr-Pro-Ala-OH (EMDB-3) 55.0 ± 1.10 100 51.4 ± 1.44 290
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